Related Experiment Video

Updated: May 20, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Antiangiogenic drugs for colorectal cancer: exploring new possibilities

Renata Ferrarotto1, Paulo M Hoff

  • 1Oncology Department, Hospital Sirio Libanes, Faculdade de Medicina da Universisade de Sao Paulo, Sao Paulo, Brazil. renataf@hotmail.com

Clinical Colorectal Cancer
|July 6, 2012
PubMed

Insights

Antiangiogenic therapies show promise for colorectal cancer treatment by targeting tumor growth. Identifying biomarkers is crucial for personalized cancer care and developing new antiangiogenic drugs.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Angiogenesis is vital for cancer development and progression.
  • Antiangiogenic therapies aim to inhibit tumor growth and have shown benefits in various cancers.
  • Colorectal cancer treatment has seen limited success with antiangiogenic drugs, with only bevacizumab and aflibercept demonstrating survival benefits in phase III trials.

Purpose of the Study:

  • To review the role of angiogenesis in colorectal cancer progression.
  • To analyze clinical data on antiangiogenic therapies in metastatic and adjuvant settings.
  • To discuss the potential of antiangiogenics beyond tumor progression and the importance of biomarkers.

Main Methods:

  • Literature review of angiogenesis in colorectal cancer.
  • Analysis of clinical trial data for antiangiogenic agents.
  • Discussion of tumor microenvironment interactions and biomarker development.

Main Results:

  • Angiogenesis is a key factor in colorectal cancer progression.
  • Bevacizumab and aflibercept are the only antiangiogenic drugs with proven survival benefits in phase III trials for colorectal cancer.
  • Personalized medicine approaches require the identification of surrogate biomarkers.

Conclusions:

  • Antiangiogenic therapies are an important area of research for colorectal cancer.
  • Further research is needed to identify effective antiangiogenic strategies and biomarkers for personalized treatment.
  • Understanding the tumor microenvironment is crucial for advancing antiangiogenic therapy.

More Related Videos

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...